Immunoassay Systems Market worth $27.15 Billion by 2023
According to the new market research report Immunoassay Systems Market is expected to reach USD 27.15 Billion by 2023 from USD 20.19 Billion in 2018, at a CAGR of 6.1%.
The increasing incidence of chronic and infectious diseases,
technological advancements in immunoassay instruments and introduction
of novel automated systems, and growth in the biotechnology and
biopharmaceutical industries are some the major factors driving the
growth of this market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436
North America held the largest share of the market in 2017
Based on region, the immunoassay market is segmented into North
America, Europe, Asia Pacific, Latin America, and the Middle East &
Africa. North America dominated the market in 2017. The large share of
this regional segment is attributed to the increasing incidence of
chronic diseases and improved healthcare infrastructure.
By technology, the enzyme-linked immunosorbent assays (ELISA) segment accounted for the largest share of the market in 2017
On the basis of technology, the immunoassay systems market is segmented
into ELISA, rapid tests, western blotting, enzyme-linked immunospot
(ELISPOT), immuno-PCR, and other immunoassay technologies. The ELISA
segment accounted for the largest share of the immunoassay systems
market in 2017. The large share of this segment can primarily be
attributed to the increasing use of immunoassay tests in cancer,
infectious diseases, and therapeutic drug level monitoring.
By product and service, the reagents and kits segment commanded the largest share of the market in 2017
On the basis product and service, this market is classified into
reagents and kits, analyzers, and software and services. In 2017, the
reagents and kits segment accounted for the largest share of the
immunoassay systems market. The large share of this segment can
primarily be attributed to the requirement of the repeat purchase of
kits and reagents, coupled with the increasing number of immunoassay
tests being performed across the globe as a result of the rising
incidence of chronic and infectious diseases.
The chemiluminescence immunoassays (CLIAs) segment led the immunoassay market in 2017
By platform, this market is classified into CLIAs, radioimmunoassays
(RIAs), colorimetric immunoassays (CIs), fluorescence immunoassays
(FIAs), and other platforms. The CLIAs segment accounted for the largest
share of the immunoassay systems market in 2017. The large share of
this segment can primarily be attributed to the low cost and high
sensitivity of CLIA-based tests.
Get Free Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=436
Key players in the immunoassay systems market
include Roche (Switzerland), Abbott Laboratories (US), Siemens
(Germany), Danaher Corporation (US), Sysmex Corporation (Japan),
bioMérieux (France), Ortho Clinical Diagnostics (US), DiaSorin (Italy),
QIAGEN (Netherlands), Thermo Fisher Scientific (US), Becton, Dickinson
and Company (US), Merck (Germany), Bio-Rad Laboratories (US), Agilent
Technologies (US), PerkinElmer (US), Quidel Corporation (US), Bio-Techne
Corporation (US), and Mindray (China).
Comments
Post a Comment